NEW YORK, NY / ACCESSWIRE / February 13, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
EXC Shareholders Click Here: https://www.zlk.com/pslra-1/exelon-corporation-loss-form?prid=5463&wire=1
GERN Shareholders Click Here: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5463&wire=1
BYND Shareholders Click Here: https://www.zlk.com/pslra-1/beyond-meat-inc-loss-form?prid=5463&wire=1
* ADDITIONAL INFORMATION BELOW *
Exelon Corporation (NYSE:EXC)
EXC Lawsuit on behalf of: investors who purchased February 9, 2019 - November 1, 2019
Lead Plaintiff Deadline: February 14, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/exelon-corporation-loss-form?prid=5463&wire=1
According to the filed complaint, during the class period, Exelon Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) Exelon subsidiary Commonwealth Edison's revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company's public statements were materially false and misleading at all relevant times.
Geron Corporation (NASDAQ:GERN)
GERN Lawsuit on behalf of: investors who purchased March 19, 2018 - September 26, 2018
Lead Plaintiff Deadline: March 23, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/geron-corporation-et-al-loss-form?prid=5463&wire=1
The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.
Beyond Meat, Inc. (NASDAQ:BYND)
BYND Lawsuit on behalf of: investors who purchased May 2, 2019 - January 27, 2020
Lead Plaintiff Deadline: March 30, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/beyond-meat-inc-loss-form?prid=5463&wire=1
According to the filed complaint, during the class period, Beyond Meat, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Beyond Meat's termination of its supply agreement with Don Lee constituted a breach of that agreement, thus exposing the Company to foreseeable legal liability and reputational harm; (ii) Beyond Meat and certain of its employees had doctored and omitted material information from a food safety consultant's report, which the Company represented as accurate to Don Lee; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: